Metagenomi (MGX) Revenue & Revenue Breakdown
Metagenomi Revenue Highlights
Latest Revenue (Y)
$44.76M
Latest Revenue (Q)
$8.51M
Metagenomi Revenue by Period
Metagenomi Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $44.76M | 160.21% |
| 2022-12-31 | $17.20M | 6978.19% |
| 2021-12-31 | $243.00K | - |
Metagenomi generated $44.76M in revenue during NA 2023, up 160.21% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Metagenomi Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | $8.51M | 106.28% |
| 2025-03-31 | $4.13M | -57.07% |
| 2024-12-31 | $9.61M | -16.50% |
| 2024-09-30 | $11.51M | -42.45% |
| 2024-06-30 | $20.01M | 79.30% |
| 2024-03-31 | $11.16M | -10.00% |
| 2023-12-31 | $12.40M | 0.29% |
| 2023-09-30 | $12.36M | 9.05% |
| 2023-06-30 | $11.34M | 30.96% |
| 2023-03-31 | $8.66M | 54.73% |
| 2022-12-31 | $5.59M | 13.88% |
| 2022-09-30 | $4.91M | 46.83% |
| 2022-06-30 | $3.35M | - |
| 2022-03-31 | $3.35M | - |
Metagenomi generated $8.51M in revenue during Q2 2025, up 106.28% compared to the previous quarter, and up 76.29% compared to the same period a year ago.
Metagenomi Revenue Breakdown
Metagenomi Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Jun 25 | Mar 25 |
|---|---|---|
| Operating Segments | $8.51M | $4.13M |
Latest
Metagenomi's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: Operating Segments (100.00%).
Metagenomi Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| COYA | Coya Therapeutics | $3.55B | $163.62K |
| ZNTL | Zentalis Pharmaceuticals | $67.42M | - |
| MGX | Metagenomi | $44.76M | $8.51M |
| SEER | Seer | $14.17M | $4.21M |
| IRD | Opus Genetics | $10.99M | $4.37M |
| SRZN | Surrozen | $10.65M | $983.00K |
| TCRX | TScan Therapeutics | $2.82M | - |
| IMDX | Insight Molecular Diagnostics | $1.88M | $518.00K |
| ATYR | aTyr Pharma | $353.00K | - |
| QNCX | Quince Therapeutics | - | - |